Livzon Pharmaceutical Group Inc. has formally adopted the Terms of Reference for its Environmental, Social and Governance (ESG) Committee, effective 23 October 2025. Under these guidelines, the ESG Committee will comprise at least five directors, with a majority required to be independent non-executive directors. The Board will nominate and appoint members by more than half of its total membership, ensuring continuity and compliance with both the Shenzhen and Hong Kong Listing Rules.

The ESG Committee is charged with reviewing Livzon’s ESG policies and objectives, supervising the company’s ESG management framework, and identifying relevant risks and opportunities. Its responsibilities also include overseeing the establishment of ESG goals, guiding the preparation and disclosure of ESG reports, and providing recommendations on policy updates. Committee meetings will be held at least once a year, with the option for additional meetings if required, and all resolutions will be reported to the Board for approval.

The newly outlined terms authorize the ESG Committee to access necessary information and consult external experts when needed. The committee’s work will be supported by a designated Working Group, which will handle implementation tasks and provide regular updates. These measures are intended to ensure transparency, fulfill regulatory obligations, and maintain alignment with evolving global standards in sustainability management.